For example, several genes involved in B cell-associated immune processes were biased in most tumor types (Fig. 2c), including membrane-spanning 4-domain A1 (MS4A1), immunoglobulin lambda-like polypeptide 1 (IGLL1), B-cell antigen receptor complex-associated protein alpha chain (CD79A), C–X–C motif chemokine receptor 5 (CXCR5), and immune receptor translocation-associated protein 2 (FCRL5), suggesting that inflamed tumor types were also B cell-rich tumors, which has been proven to be a key factor determining sensitivity to immunotherapy20,21. The gene discussed is FCRL5; the disease is neoplasm.